Regular readers will remember that Vertex has taken a commanding lead in the race with Schering — to bring the next generation of Hep C drugs to market in the United States. This news, this morning, extends that lead. A Phase IIa trial, conducted by Vertex, has shown strong interim results.
When it rains, lately, in New Jersey — in Kenilworth — it pours.
